News and events
NEUmiRNA Therapeutics Secures Third Innobooster Grant of 5 Million DKK to Propel Epilepsy Disease-Modifying Therapy to the Clinic
This substantial funding will be allocated to advance NEUmiRNA's groundbreaking disease-modifying therapy for epilepsy to the clinic, bringing hope to the circa 50 million patients affected by epilepsy worldwide.
Read more in the press release below
01.03.2024
NEUmiRNA Therapeutics awarded $650.000 grant from The Michael J. Fox Foundation to advance development of RNA Therapies for Parkinson’s Disease
In collaboration with Motac Neuroscience and Center for RNA Medicine (Aalborg University)
Read the press release below
08.01.2024
Review on Adenosine in the treatment of neuropathic pain published in the Scandinavian Journal of Pain
Henrik Klitgaard (Co-Founder, PhD) and Stine Norman-Hansen (Senior Scientist, PhD) authored this topical review together with leading pain expert, Prof. Lars Arendt-Nielsen
15.12.2023
NEUmiRNA wins Nordic Star Award Pitch competition as start-up with the highest investment potential at NLS DAYS 2023
Read the main highlights from NLS Days 2023 here:
30.11.2023
NEUmiRNA featured on MedWatch: “RNA startup from Copenhagen begins hunting for large capital raising”
With a new CEO in place, Sunstone-backed Neumirna aims to land a three-digit million sum in the first half of 2024.
10.11.2023
NEUmiRNA selected as one of the young, high potential life science companies for the Nordic Stars Pitch Competition!
The future of Nordic life science is here! 🚀
An jury has worked hard to select the 30 young, high-potential life science companies that have been shortlisted for the prestigious ⭐ Nordic Star pitch competition ⭐ at #NLSDays in Copenhagen. This premier Nordic event will take place on November 29-30, where these ambitious startups will pitch their innovative ideas and compete for two prestigous awards.
To see the list of the selected companies, click here: https://lnkd.in/dzbaw3-a
05.10.2023
NEUmiRNA awarded a Eureka Network EUROSTARS grant of 1.65M€ in collaboration with Motac Neuroscience Ltd, the Université de Bordeaux and the Center for RNA Medicine!
This grant will enable us to develop innovative RNA therapies which could revolutionize the treatment of Parkinson's Disease 🧠 . Stay tuned for updates and progress reports on this exciting project!
01.10.2023
3-year Industrial Postdoc Fellowship awarded to Lluís Riera-Ponsatí
This grant from the Innovation Fund Denmark (IFD) will help us in further establishing our drug discovery pipeline, aimed at developing disease-modifying RNA Therapies for Parkinson's Disease at NEUmiRNA, in collaboration with Aalborg University and the Center for RNA Medicine (CRM).
01.10.2023
NEUmiRNA at AES2023 Annual Meeting in Orlando, US
Our CEO Janine Erler will be presenting a late-breaking abstract, entitled “Therapeutic Inhibition of microRNA-134 Potently Suppresses Spontaneous Recurrent Seizures in Mice with Pre-existing Drug-resistant Temporal Lobe Epilepsy” at the AES meeting in Orlando, December 1-5. Come by if you are around!
06.10.2023
Critical review from NEUmiRNA published in Epilepsia
RNA therapeutics for epilepsy: An emerging modality for drug discovery
13.10.2023
American Epilepsy Society (AES) 2022
NEUmiRNA Therapeutics attended the annual AES meeting in Nashville from the 2nd to the 6th of December. Co-founder Henrik Klitgaard and Stine Hansen presented data on the effects of targeting microRNAs in drug resistant epilepsy.
6.12.2022
New publication on RNA Biology
A comprehensive review on RNA Therapeutics for the treatment of neurmouscular disorders is out now on the latest issue of RNA Biology.
Check it out here
10.10.2021
NEUmiRNA on MedWatch “RNA startup will create a new future for treating neurological disorders”
The capital venture firms Sunstone and Innovestor join the board at NEUmiRNA.
13.12.2022
NEUmiRNA at the EVF global accelerator course
In 2021, NEUmiRNA was selected and awarded by the US Epilepsy Foundation as being a promising start-up to advance new treatments for people with epilepsy in the EVF global accelerator course for start-up companies.
10.10.2021